Foundayo (Orforglipron) Side Effects and Safety
How common nausea and constipation really are, the serious risks that make this a prescription-only medicine, who must not take it, and the drug interactions that change the dose.
Part of the Overweight and Obesity condition guide.
The headline: Most people taking Foundayo experience some side effects, and for most they're digestive, manageable, and worst in the days after a dose increase. A smaller number of risks are serious—and they're the reason this is a prescription-only medicine assessed by a clinician rather than something you can simply order.
Foundayo Safety Assessment
Access Doctor provides Foundayo (orforglipron) following a GPhC-regulated online consultation with our pharmacist independent prescribers, including a full medical history and medicines review.
Order Foundayo →Common side effects
These figures come from the clinical trials, comparing people taking Foundayo with people taking a dummy tablet. The placebo column matters: some of what people notice would have happened anyway.
| Side effect | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhoea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Indigestion | 4% | 12% | 16% | 13% |
| Abdominal pain | 7% | 13% | 14% | 14% |
| Headache | 7% | 8% | 9% | 9% |
| Hair loss | 2% | 4% | 4% | 5% |
Two patterns are worth noticing. Side effects increase with dose—which is the whole reason for the slow titration schedule. And they tend to ease with time at a given dose, typically over days to a few weeks.
Managing the common ones
Nausea
Smaller meals, eating more slowly, stopping before you feel full, and going easy on fatty or fried food. Tell your prescriber if it's stopping you eating or drinking properly.
Constipation
Fluids, fibre and movement. Persistent constipation is worth flagging rather than tolerating, and your pharmacist can advise on short-term options.
Diarrhoea and vomiting
The main risk here is dehydration, which is also the route to kidney problems. Keep fluids up and seek advice if you can't keep them down.
Hair loss
Usually related to the rate of weight loss rather than the drug directly, and usually temporary. Adequate protein intake helps.
Serious risks
Thyroid tumours (boxed warning)
Orforglipron carries a boxed warning about the risk of thyroid C-cell tumours, including medullary thyroid carcinoma. This warning applies across the GLP-1 receptor agonist class, based on findings in rodents. It isn't known whether these medicines cause such tumours in humans, and orforglipron itself didn't produce them in rodent studies—but the class warning and contraindication still apply.
Tell your doctor straight away if you notice a lump or swelling in your neck, hoarseness that doesn't go away, trouble swallowing, or shortness of breath.
Pancreatitis
Inflammation of the pancreas has been reported with GLP-1 medicines. Seek urgent medical attention for severe, persistent abdominal pain—classically in the upper abdomen, sometimes radiating to the back—with or without vomiting. Stop taking the medicine and get assessed.
Severe gastrointestinal reactions
Foundayo slows stomach emptying, and in some people this becomes severe. It shouldn't be used by anyone with severe gastroparesis.
Dehydration and acute kidney injury
Vomiting and diarrhoea can cause volume depletion, which in some cases has led to acute kidney injury, including in people with no previous kidney problems. People taking diuretics, ACE inhibitors or ARBs are at greater risk.
Hypoglycaemia
Foundayo alone rarely causes low blood sugar, because its effect on insulin is glucose-dependent. Combined with insulin or a sulfonylurea, the risk is real, and those doses may need reducing.
Gallbladder problems
Rapid weight loss of any cause raises the risk of gallstones. Report persistent upper-right abdominal pain, fever, or yellowing of the skin or eyes.
Diabetic retinopathy
In people with type 2 diabetes and existing retinopathy, rapid improvement in blood sugar control has been associated with temporary worsening. Eye monitoring may be advised.
Anaesthesia and sedation
Delayed stomach emptying increases the risk of pulmonary aspiration—stomach contents entering the lungs—during general anaesthesia or deep sedation, even after normal fasting. Tell any surgeon, anaesthetist, endoscopist or dentist that you're taking Foundayo, well before any planned procedure. This is one of the most important and most commonly overlooked points about this class of medicine.
Allergic reactions
Serious hypersensitivity reactions have been reported. Seek emergency help for swelling of the face, lips, tongue or throat, difficulty breathing, or a severe rash.
Who should not take Foundayo
Foundayo is contraindicated—meaning it must not be used—if you have:
- a personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- a serious hypersensitivity to orforglipron or any of the tablet's ingredients
It should also not be taken alongside another GLP-1 receptor agonist, such as Mounjaro, Wegovy, Saxenda or Wegovy tablets.
Additional caution or assessment applies if you have a history of pancreatitis, severe gastrointestinal disease including severe gastroparesis, significant kidney or liver impairment, diabetic retinopathy, or an eating disorder.
Pregnancy, breastfeeding and contraception
Foundayo may cause harm to an unborn baby and should be stopped as soon as pregnancy is recognised. It isn't recommended in pregnancy or while trying to conceive.
There's a specific and easily missed point about contraception. Because Foundayo slows stomach emptying, it can reduce the absorption of oral contraceptives. Use an additional non-oral method of contraception—or switch to a non-oral method—for 30 days after starting Foundayo and for 30 days after every dose increase. If you use the pill, our guide to alternatives to the contraceptive pill may be useful to read alongside this.
Drug interactions
Tell your prescriber about everything you take, including over-the-counter medicines, herbal remedies and supplements.
| Interacting medicine | What happens | What it means |
|---|---|---|
| Strong CYP3A4 inhibitors — e.g. ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors | Raise orforglipron levels | Maximum Foundayo dose reduced to 9 mg daily |
| Strong CYP3A4 inducers — e.g. rifampicin, carbamazepine, phenytoin, St John's wort | Lower orforglipron levels | Avoid; moderate inducers need monitoring |
| Simvastatin | Roughly doubles active metabolite exposure | Limit simvastatin to 20 mg daily |
| Oral contraceptives | Absorption may be reduced | Backup non-oral contraception for 30 days after starting and after each dose increase |
| Insulin or sulfonylureas | Increased hypoglycaemia risk | Doses may need reducing |
| Other GLP-1 receptor agonists | Not appropriate together | Do not combine |
| Other oral medicines generally | Delayed gastric emptying can alter absorption | Mention any medicine with a narrow therapeutic range |
When to seek urgent help
Get immediate medical attention if you have severe, persistent abdominal pain, especially radiating to the back; swelling of the face, lips, tongue or throat, or difficulty breathing; signs of severe dehydration such as dizziness on standing, passing very little urine or confusion; a neck lump, persistent hoarseness or difficulty swallowing; yellowing of the skin or eyes; or symptoms of very low blood sugar that don't respond to treatment. In an emergency, call 999.
Reporting side effects in the UK
If you experience a side effect from any medicine, you can report it directly through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk, or via the Yellow Card app. Orforglipron is a newly authorised medicine under additional monitoring, so reporting is particularly valuable—it's how the safety picture for new medicines is built.
Order Foundayo with Clinical Support
Every Access Doctor consultation includes a full medical history and medicines review by a GPhC-registered pharmacist independent prescriber, with free clinical support if a side effect concerns you once you've started.
Order Foundayo →Frequently Asked Questions
Do the side effects of Foundayo go away?
The digestive side effects usually ease within days to a few weeks at a stable dose, and they tend to return briefly after each dose increase before settling again. This pattern is the reason the titration schedule allows a minimum of 30 days at each strength. Side effects that are severe, or that stop you eating and drinking properly, should be reported to your prescriber rather than tolerated.
Is Foundayo safer than GLP-1 injections?
It is not injected, which some people prefer, but it belongs to the same class of medicine and carries broadly the same risk profile, including the boxed warning about thyroid C-cell tumours. Being a tablet does not make it a milder medicine. It does avoid injection-site reactions, and it has its own specific CYP3A4 drug interactions that the injections do not have.
Can I drink alcohol while taking Foundayo?
There is no absolute prohibition, but alcohol can worsen nausea and irritate the stomach, and it raises the risk of low blood sugar in people who also take insulin or a sulfonylurea. Alcohol also adds calories that work against the purpose of treatment. Moderation is sensible, and you should raise it with your prescriber if you drink regularly.
Will I lose muscle as well as fat on Foundayo?
Some loss of lean mass accompanies substantial weight loss by any method, including diet alone. Adequate protein intake and regular resistance exercise help preserve muscle during treatment. If you are losing weight very quickly, tell your prescriber, because a slower rate is generally better for preserving lean tissue.
Does Foundayo affect the contraceptive pill?
It can. Because Foundayo slows stomach emptying, it may reduce the absorption of oral contraceptives. The labelling advises using an additional non-oral method of contraception, or switching to a non-oral method, for 30 days after starting Foundayo and for 30 days after every dose increase. This is one of the most commonly missed points about the medicine, so raise it specifically with your prescriber.
What happens if I stop taking Foundayo?
Appetite typically returns and weight regain is common across this class of medicine. Discuss any plan to stop with your prescriber rather than stopping abruptly on your own, so that you can put diet, activity and follow-up support in place. If you have been off treatment for around a week or more and want to restart, contact your prescriber first, because you may need to restart at a lower dose.
Do I need to tell my surgeon or dentist that I take Foundayo?
Yes, and well in advance of any planned procedure. Delayed stomach emptying increases the risk of pulmonary aspiration, where stomach contents enter the lungs, during general anaesthesia or deep sedation, even after normal fasting. Tell any surgeon, anaesthetist, endoscopist or dentist that you are taking Foundayo. This is one of the most important and most commonly overlooked points about this class of medicine.
Safety checks at Access Doctor
Access Doctor is a GPhC-registered UK online pharmacy. Our consultations cover thyroid history, family history of medullary thyroid cancer or MEN 2, pancreatitis, gastrointestinal conditions, kidney and liver function, eating disorder history, mental health and your full medicines list—including anything bought over the counter. Where treatment isn't clinically appropriate, we say so and no medicine is supplied.
Weight Loss · Rx
Foundayo (Orforglipron)
Once-daily GLP-1 tablet, supplied in original sealed UK packaging with the patient information leaflet.
View product →Weight Loss · Rx
Wegovy Tablets
Oral semaglutide, the other licensed GLP-1 tablet, with a different interaction profile.
View product →See all of our weight loss treatments.
References
- US Food and Drug Administration. FOUNDAYO (orforglipron) tablets — Prescribing Information. 2026. accessdata.fda.gov
- Eli Lilly and Company. Complete ATTAIN-1 results published in the New England Journal of Medicine. 2026. lilly.gcs-web.com
- Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. 10 August 2026. gov.uk
- Medicines and Healthcare products Regulatory Agency. Yellow Card scheme. yellowcard.mhra.gov.uk
- National Institute for Health and Care Excellence. Obesity: identification, assessment and management (CG189). nice.org.uk
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. In a medical emergency, call 999.